--- title: "Glucosamine/Chondroitin and Mortality in a US NHANES Cohort" description: "Regular use of glucosamine/chondroitin supplements is associated with a lower risk of death from all causes and cardiovascular disease in US adults." url: "https://magellanlongevity.com/study/glu_nhanes.md" canonical: "https://magellanlongevity.com/study/glu_nhanes.html" html: "https://magellanlongevity.com/study/glu_nhanes.html" type: "study" study_key: "glu_nhanes" journal: "Frontiers in Pharmacology" year: 2020 pmid: "33219063" doi: "10.3122/jabfm.2020.06.200110" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Glucosamine/Chondroitin and Mortality in a US NHANES Cohort [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Glucosamine/Chondroitin and Mortality in a US NHANES Cohort **HTML version:** https://magellanlongevity.com/study/glu_nhanes.html · **In the Magellan app:** https://magellanlongevity.com/#/study/glu_nhanes ## Citation | Field | Value | | --- | --- | | Journal | Frontiers in Pharmacology | | Year | 2020 | | PMID | [33219063](https://pubmed.ncbi.nlm.nih.gov/33219063/) | | DOI | [10.3122/jabfm.2020.06.200110](https://doi.org/10.3122/jabfm.2020.06.200110) | | Study key | glu_nhanes | ## Takeaway Regular use of glucosamine/chondroitin supplements is associated with a lower risk of death from all causes and cardiovascular disease in US adults. ## The question Does regular consumption of glucosamine/chondroitin affect overall and cardiovascular (CVD) mortality in US adults? ## Hypothesis Previous studies suggest an association between glucosamine/chondroitin intake and mortality, leading to the hypothesis that regular consumption may be linked to lower mortality rates in a national US sample. ## Methods This study analyzed combined data from 16,686 participants in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2010, linked with the 2015 Public-use Linked Mortality File. Cox proportional hazards models were used to assess the association between glucosamine/chondroitin use and all-cause and CVD mortality. ## Results During a median follow-up of 107 months, there were 3366 total deaths (20.17%), with 674 (20.02%) attributed to CVD. Participants taking glucosamine/chondroitin for a year or longer (3.94% of the sample) showed a 39% reduction in all-cause mortality (HR = 0.61) and a 65% reduction in CVD mortality (HR = 0.35) after adjusting for age. After further adjustment for age, sex, race, education, smoking status, and physical activity, the association remained significant, with a 27% reduction in all-cause mortality (HR = 0.73) and a 58% reduction in CVD mortality (HR = 0.42). ## Conclusion Regular intake of glucosamine/chondroitin is associated with lower all-cause and CVD mortality in a national US cohort. These findings are consistent with previous studies in other populations. ## Limitations The study design was observational, which means it cannot establish a causal link between glucosamine/chondroitin intake and reduced mortality. Prospective studies are needed to confirm these findings. ## Verbatim from the abstract > Glucosamine/chondroitin use was associated with reduced all-cause mortality in a nationally representative U.S. cohort. ## Adjusted Reduction in Mortality with Glucosamine/Chondroitin Use | Measure | Percentage Reduction (%) | | --- | --- | | All-Cause Mortality (Age-Adjusted) | 39 | | CVD Mortality (Age-Adjusted) | 65 | | All-Cause Mortality (Multivariable-Adjusted) | 27 | | CVD Mortality (Multivariable-Adjusted) | 58 | *Percentage reduction in mortality risk associated with regular glucosamine/chondroitin intake, adjusted for various factors.* ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | D-Glucosamine | Moderate evidence | [D-Glucosamine Sulfate](https://magellanlongevity.com/p/197.md) | | Osteo Bi-Flex (Triple Strength + Joint Shield) | Moderate evidence | [Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield)](https://magellanlongevity.com/p/217.md) | | Glucosamine + Chondroitin (+ MSM) | Moderate evidence | [Glucosamine Chondroitin MSM (with OptiMSM)](https://magellanlongevity.com/p/218.md) | ## Reference 1. **Glucosamine/Chondroitin and Mortality in a US NHANES Cohort** Frontiers in Pharmacology 2020 · [PMID 33219063](https://pubmed.ncbi.nlm.nih.gov/33219063/) · [DOI 10.3122/jabfm.2020.06.200110](https://doi.org/10.3122/jabfm.2020.06.200110) > Glucosamine/chondroitin use was associated with reduced all-cause mortality in a nationally representative U.S. cohort. ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/glu_nhanes.html#page","url":"https://magellanlongevity.com/study/glu_nhanes.html","name":"Glucosamine/Chondroitin and Mortality in a US NHANES Cohort","description":"Regular use of glucosamine/chondroitin supplements is associated with a lower risk of death from all causes and cardiovascular disease in US adults.","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/glu_nhanes.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Glucosamine/Chondroitin and Mortality in a US NHANES Cohort","item":"https://magellanlongevity.com/study/glu_nhanes.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/glu_nhanes.html#study","name":"Glucosamine/Chondroitin and Mortality in a US NHANES Cohort","headline":"Glucosamine/Chondroitin and Mortality in a US NHANES Cohort","datePublished":"2020","isPartOf":{"@type":"Periodical","name":"Frontiers in Pharmacology"},"identifier":"PMID:33219063","url":"https://pubmed.ncbi.nlm.nih.gov/33219063/","sameAs":"https://doi.org/10.3122/jabfm.2020.06.200110","abstract":"Regular use of glucosamine/chondroitin supplements is associated with a lower risk of death from all causes and cardiovascular disease in US adults."}]} ``` ## Related on Magellan Longevity - [D-Glucosamine Sulfate](https://magellanlongevity.com/p/197.md) — product graded on this and related evidence - [Osteo Bi-Flex Triple Strength (Glucosamine Chondroitin + Joint Shield)](https://magellanlongevity.com/p/217.md) — product graded on this and related evidence - [Glucosamine Chondroitin MSM (with OptiMSM)](https://magellanlongevity.com/p/218.md) — product graded on this and related evidence - [Associations of regular glucosamine use with all-cause and cause-specific mortality: a…](https://magellanlongevity.com/study/glu_biobank.md) - [Genetically predicted glucosamine and longevity: A Mendelian randomization study](https://magellanlongevity.com/study/glu_mr.md) - [Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis](https://magellanlongevity.com/study/boswellia_oa.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).